DLC1: A Protein Targeted for Drug Development (G10395)

Target Name: DLC1

NCBI ID: G10395

DLC1

DLC1: A Protein Targeted for Drug Development

DLC1 (ARHGAP7) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the ARHGAP gene family, which is known for its role in cell signaling and cytoskeletal organization.

One of the unique features of DLC1 is its ability to interact with the protein TEC452, which is also known as p120GAP. TEC452 is a protein that is involved in the regulation of cell signaling pathways, and it is thought to play a role in the development and progression of a variety of diseases, including cancer.

DLC1 has been shown to interact with TEC452 in a variety of ways, including through the formation of a protein-protein interaction (PPI) complex. This interaction between DLC1 and TEC452 is thought to be important for the regulation of cell signaling pathways and for the function of the ARHGAP gene family.

In addition to its role in cell signaling, DLC1 is also a potential drug target. Several studies have shown that DLC1 is downregulated in a variety of tissues and that it is involved in the development of a variety of diseases, including cancer. Therefore, it is thought to be an attractive target for drug development.

One of the challenges in studying DLC1 as a drug target is its complex structure. DLC1 is a large protein with multiple domains, and it is not clear how all of these domains work together to interact with TEC452 and regulate cell signaling pathways.

To overcome this challenge, researchers have used a variety of techniques to study the structure and function of DLC1. These techniques include biochemical assays, such as protein-protein interaction assays, and cell-based assays, such as cell-based assays of DLC1-TEC452 interaction.

One of the most interesting findings from these studies is that DLC1 appears to play a role in the regulation of cell signaling pathways that are important for the development and progression of cancer. For example, several studies have shown that DLC1 is involved in the regulation of the PI3K/Akt signaling pathway, a pathway that is important for the growth and survival of cancer cells.

In addition to its role in cancer development, DLC1 is also thought to be involved in the regulation of other signaling pathways that are important for the development and progression of other diseases, including cardiovascular disease and neurodegenerative diseases.

Overall, DLC1 is a protein that is involved in a variety of signaling pathways and is thought to be an attractive target for drug development. While more research is needed to fully understand its function and its potential as a drug target, its interactions with TEC452 and its involvement in the regulation of cell signaling pathways suggest that it is an important protein that should be further studied.

Protein Name: DLC1 Rho GTPase Activating Protein

Functions: Functions as a GTPase-activating protein for the small GTPases RHOA, RHOB, RHOC and CDC42, terminating their downstream signaling. This induces morphological changes and detachment through cytoskeletal reorganization, playing a critical role in biological processes such as cell migration and proliferation. Also functions in vivo as an activator of the phospholipase PLCD1. Active DLC1 increases cell migration velocity but reduces directionality. Required for growth factor-induced epithelial cell migration; in resting cells, interacts with TNS3 while PTEN interacts with the p85 regulatory subunit of the PI3K kinase complex but growth factor stimulation induces phosphorylation of TNS3 and PTEN, causing them to change their binding preference so that PTEN interacts with DLC1 and TNS3 interacts with p85 (PubMed:26166433). The PTEN-DLC1 complex translocates to the posterior of migrating cells to activate RHOA while the TNS3-p85 complex translocates to the leading edge of migrating cells to promote RAC1 activation (PubMed:26166433)

The "DLC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DLC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets